Skip to main content

Deal Alert: Fulcrum Venture India invests INR 21.82 crores in ‘Shield Healthcare Pvt Ltd’

Fulcrum Venture India, a highly successful early stage venture capital investor started in 2000 by Krishna Ramanathan as a proprietary fund, today announced an investment of INR 21.82 crores in Shield Healthcare Pvt Ltd a pharmaceutical company within the branded formulations space. The company will use the proceeds to fund its business geographically and vertically integrate a manufacturing unit. As an integral part of this deal, Krishna Ramanathan, Founder-Partner, Fulcrum Venture India will join the Board of Directors of the Company. 

Commenting on the occasion, Krishna Ramanathan said, “Fulcrum Venture India is happy to partner with Shield Healthcare under the leadership of Mr L. Mahadevan and looks forward to the company scaling up over the next 5 to 7 years under his leadership. The company carries a strong product catalogue and with the growth of new products in the Gynaecologist and Consultant Physician segments. Fulcrum expects Shield revenue to increase significantly over the coming year, thereafter growing exponentially to INR 100Cr by 2016 yielding an EBIDTA in the range of 26% - 30% according to Pharma Industry standards. We also consider the valuation attractive given Fulcrum’s deep domain knowledge in the formulations business.” 

Shield with a top line of INR 24Cr, in FY 2012, moved into expansion mode recently to enlarge its southern and eastern presence into a pan Indian one. The company will close at a top line of INR 31Cr, in FY 2013. To realize its expansion plans Shield decided to launch a manufacturing unit, where in Fulcrum saw as a golden investment opportunity. It estimates the Factory and SBU will break even in the next 2 years, while the overall company is cash flow positive. Fulcrum believes that further investment into geographical expansion would turn positive cash-flow sooner. Shield, an ISO-9000:2008 certified organization, is aiming for UK MHRA accreditation by 2013 and expects US FDA approval by 2014. 

The main strength of Shield lies in its outstanding management team and focus on building very powerful brands, while phasing out other less promising ones. In keeping with our game changing investment policy Fulcrum has been active in developing strategies for expanding the sales division and future options of the factory. Shield is now focused on brands in the Gynaecology and Infertility segment; Fulcrum expects its revenue to rapidly increase in the next financial year due to the inherent value Shield has built into the product assets. 

Fulcrum has been focusing on early stage investing since its inception in 2000 and has a successful track record for offering financial support to promising start ups and SMEs in a variety of sectors such as Pharma, Niche Retail, Consumer Durables, Education, IT & Technology. Fulcrum Venture India continues to identify, fund and manage, promising investment opportunities and facilitate growth in the neglected SME sector. 

About Fulcrum Venture India 

Fulcrum has been focusing on early stage investing since its inception in 2000 and has a successful track record for offering financial support to promising start ups in a variety of sectors such as Pharma, Niche Retail, Consumer Durables, Education, IT & Technology. Fulcrum partners with promising SME’s to create good top line growth and high Return on equity. On average Fulcrum’s investments have, 8.95x cash invested since 2000. We focus on business fundamentals and partner ambitious management with big unique ideas in stable markets. For more information, please visit www.fulcrumventureindia.com 

About Shield Healthcare Pvt Ltd

Shield started operations in 1995 under the guidance and able leadership of Mr L. Mahadevan. Shield is currently present across 10 states with strong presence in Tamil Nadu and Andhra Pradesh. The company has robust plans to build a pan India presence in the next few years. Shield today is recognized as an integrated pharmaceutical company with core competencies in the development and manufacture of strong products in the Infertility segment, Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms and drug discovery, as well as a robust pipeline for launching new products. For more information, please visit www.shieldhealthcare.co.in 

Venture Intelligence is the leading provider of data and analysis on Private Company Financials, Transactions (private equity, venture capital and M&A) & their Valuations in India. Click Here to view our products list including the Free Deal Digest Weekly: India's First & Most Exhaustive Transactions Newsletter.

Popular posts from this blog

PE-VC investments decline 8% to $6.2 B in Q1'24

Press Release: Private Equity - Venture Capital (PE-VC) firms invested over $6.2 Billion (across 205 deals) in Indian companies during the first three months of 2024, shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. (Note: These figures include Venture Capital type investments, but exclude PE investments in Real Estate). The investment amount represents a 8% fall over the $6.7 Billion (across 242 deals) invested in the same period during 2023 and also down by 6% when compared to the immediate previous quarter (which witnessed $6.6 Billion being invested across 200 deals). Deal volumes in Q1'24 also declined 15% compared to Q1'23 and were up by 3% compared to the immediate previous quarter.  Q1’24 witnessed 8 mega deals ($100 M+ rounds) worth $3.5 Billion, compared to 17 such investments (worth $3.6 Billion) in Q1’23 and 15 such deals (worth $4.1 Billion) in the immediate previous quarter....

Avendus tops League Table for Transaction Advisors to PE deals in H1'24

Citi and Ambit claim the No.2&3 slots Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions in H1’2024 advising 12 deals worth $2.4 Billion. Citi stood second, having advised 1 deal worth $2 Billion. Ambit followed with 7 deals worth $797 million. Kotak Mahindra Capital ($735 million across 2 deals) and Ernst & Young ($657 million across 7 deals) completed the top five for H1’ 2024. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE and M&A transactions advised by Financial and Legal Advisory firms. Among the larger deals in the latest quarter, Citi, KPMG , Ernst & Young advised $2 Billion acquisition of the Indian business of American Tower Corporation by Brookfield . Avendus, Ernst & Young, JM Financial, Barclays and KPMG advised $ 554 million acquisition of Shriram Housing Finance by Warb...

AZB tops League Table for Legal Advisors to PE deals in H1’24

Trilegal and Khaitan & Co. claim the No.2 & No.3 slots AZB & Partners (AZB) topped the Venture Intelligence League Table for Legal Advisor to Private Equity Transactions in H1 2024 advising 41 deals worth $5.4 Billion. It was followed by Trilegal ($5.1 Billion across 54 deals) and Khaitan & Co. (4.8 Billion across 46 deals) in the second and third spot respectively. Cyril Amarchand Mangaldas (CAM) ($2.9 Billion across 34 deals) and Talwar Thakore & Associates ($2.4 Billion across 9 deals) completed the top five. Among the larger Private Equity deals during H1’2024, Khaitan & Co., Talwar Thakore & Associates, S&R Associates ,and Trilegal a dvised the $2 Billion acquisition of the Indian business of American Tower Corporation by Brookfield which was the largest PE-VC investment in 2024 . AZB advised the $900 Million acquisition of Altimetrik by TPG Capital and the $840 Million acquisition of Healthium Medtech by KKR . Resolut Partners , Khaitan & ...

Citi tops League Table for Transaction Advisors to M&A deals in H1'24

  Ernst & Young and Avendus claim the No.2 & No.3 slots Citi , which advised the  $2 Billion acquisition of the Indian business of American Tower Corporation by Brookfield,  topped the Venture Intelligence League Table for Transaction Advisors to M&A Deals   during H1 2024. Ernst & Young stood second advising 8 deals worth $1.5 billion. Avendus followed with 7 deals worth $1.2 billion. KPMG ($1.1 billion across 5 deals) and JM Financial ($900 million across 4 deals) completed the top five. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE and M&A transactions advised by Financial and Legal Advisory firms. Among the other larger M&A deals in H1 2024 (other than the  ATC-Brookfield deal) , Ernst & Young, KPMG and Deloitte advised $1.1 Billion acquisition in PNC Infratech 12 Road Projects by Highways Infrastructure Tr...

AZB & Partners tops League Table for Legal Advisors to M&A deals in H1’24

Khaitan & Co. and J Sagar Associates claim the No.2 & No.3 slots AZB & Partners topped the Venture Intelligence League Table for Legal Advisor to M&A Transactions during H1 2024 advising 37 deals worth $14.8 Billion. It was followed by Khaitan & Co. ($12.8 Billion across 32 deals) and J Sagar Associates (JSA) ($9.8 Billion across 13 deals). Cyril Amarchand Mangaldas (CAM) ($6.2 Billion across 38 deals) and Trilegal ($4.8 Billion across 20 deals) completed the top five. Among the largest M&A deals during H1 2024, AZB, JSA and Khaitan & Co. advised $8.5 Billion acquisition of Disney Hotstar by Reliance Jio . S&R Associates , Talwar Thakore & Associates (TTA), Khaitan & Co. and Trilegal advised the $2 Billion buyout deal   of  ATC India by Canadian infrastructure investor Brookfield Asset Management . CAM advised the $1.3 Billion in the acquisition of a  further  stake in Ambuja Cement  by Adani Enterprises . Among fo...